This year has seen biotechs on a rockier road, but those companies that
have continued to develop broad pipelines have fared a little better. Nektar Therapeutics (NASDAQ:NKTR)
belongs on that list, as the company continues to move forward with an
array of late-stage assets and a deep pipeline based upon its PEGylation
technology (a technology that alters pre-existing drugs to improve
efficacy, tolerability, and so on). Not only does Nektar still look
undervalued, I believe that the assumptions underlining that valuation
are still conservative enough that de-risking events (namely clinical
trial results) can add meaningful value.
Continue here:
Nektar Therapeutics Has More To Give
No comments:
Post a Comment